lianhua qingwen contraindication

Clin. Clin. Nervous system damage was described as an adverse event in 34 studies. (2010). Effect of Maxing Shigan Tang on H1N1 influenza A virus-associated acute lung injury in mice. 12 (08), 140141. Recent data indicated that orally administered LHQW capsules (100400mg/kg/day) could alleviate IBV-induced pathological change and decrease the abnormal increased inflammatory cells in lung tissues, but did not reduce the lung viral load and mortality in mice [26]. Other related clinical studies also revealed that LHQW significantly improved the symptoms in COVID-19 patients and reduced the duration of fever, fatigue and cough and so forth, which provide preliminary research evidence for clinical treatment of COVID-19 [45,46]. Trials. (2020). Lianhua Qingwen Capsules of Yiling Pharmaceutical Approved in mauritius. The trim and fill method was employed in cases where publication bias existed (Duval and Tweedie, 2000). Reports emerged indicating that this process consumed significant logistical capacity, drawing criticism about misuse of resources at a time when people were struggling with shortages of basic needs such as food and medication. Future related studies will provide accumulated evidence to clarify it. The quantitative analysis of all eligible studies. Before 7 (3), 177188. The authors report no declarations of interest. Statistical analysis was performed with Stata 14 software (Stata Corporation, College Station, TX, USA). (2020) identified 38 randomized controlled trials (RCTs) comparing LHQW with antivirals or other Chinese medicines for treating influenza and reported a lower risk of adverse reactions in the LHQW group compared to oseltamivir (RR = 0.29, 95%CI = 0.110.80), and ribavirin groups (RR = 0.29, 95%CI = 0.110.80). Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. The discovery of potential effective drugs on the market becomes one of the principal means to develop antiviral drugs for COVID-19. [Lamiaceae; 1-Menthol] (7.5g), Glycyrrhiza uralensis Fisch. The control and improvement of the present COVID-19 situation in China could not be separated from the extensive participation of TCM, which has been proven effective by the clinical studies in COVID-19 patients [41,44,48,49]. aDepartment of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, PR China, bShanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, PR China, cShanghai TCM-Integrated Institute of Vascular Anomalies, Shanghai, 200082, PR China, dDepartment of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, 310018, PR China, eDepartment of Pharmacy, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310018, PR China, fState Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Science, Nanjing University, Nanjing, 210023, PR China. From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment. No adverse treatment-related effects were reported in all the included publications (from 2009 to 2011). doi:10.13412/j.cnki.zyyl.2010.06.026. doi:10.1590/1806-9282.66.6.771, Khan, Z., Karata, Y., and Rahman, H. (2020). There was no statistically significant difference in the incidence of abnormal white blood cells and reticuloendothelial system between the LHQW group and the conventional drug group (RR = 1.00, 95% CI = 0.382.62, p = 1.000). Lianhua Qingwen can be a complementary strategy for treating COVID-19. [citation needed]. and transmitted securely. (Jinyinhua), Ephedra sinica Stapf (Mahuang), Armeniacae Amarum Semen (Kuxingren), Gypsum Fibrosuum (Shigao), Isatis tinctoria L. (Banlangen), Dryopteridis Crassirhizomatis Rhizoma (Mianmaguanzhong), Houttuynia cordata Thunb. Wang Z., Chen X., Lu Y., Chen F., Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and western medicine treatment. A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. Study on the network pharmacology and evidences of Lianhua Qingwen in the treatment of Novel Coronavirus (2019 nCoV) Pneumonia. China Central Television News (2020). LQ15H280003), the Clinical Research Projects of Zhejiang Medical Association (No. Potential publication bias was assessed using Funnel plot, Beggs and Eggers test. Chin. [13], A 2020 "randomized controlled trial" of LHQW involving Zhong was also found in April 2022 to have undisclosed funding from Yiling Pharmaceuticals, forcing an erratum. Beggs test and Eggers test detected no visible publication bias for data from pooled studies and disease evaluation. There are multiple drug trials going on, but there are no specific anti-SARS-CoV-2 drugs or vaccines till now. Ni L., Zhou L., Zhou M., Zhao J., Wang D.W. Evid. 343, d5928. Ther. Experimental study on prevention and treatment of influenza virus FM1 infection in mice by Lianhua Qingwen capsule. J. Exp. Wang et al. Effects of Four Types of Integrated Chinese and Western Medicines for the Treatment of Covid-19 in china: a Network Meta-Analysis. 1: An overview of approach to pharmacokinetics-based identification of potential therapeutic compounds from LianhuaQingwen, a Chinese herbal used as treatment for COVID-19. Traditional Med. (japanese honeysuckle) flower 27.41 mg, gypsu . In recent years, LHQW has been registered to obtain marketing authorization in Canada, Brazil, Singapore, Thailand, the Philippines, Kuwait and other countries under the designation Chinese patent medicine, medicine, physical natural health products, food supplement, modern botanical medicine or natural medicine (Yiling Pharmaceutical, 2020). This study was supported by the COVID-19 Pneumonia of Traditional Chinese Medicine Emergency Project, State Administration of Traditional Chinese Medicine of the Peoples Republic of China (2020ZYLCYJ02-1). The current meta-analysis was performed to evaluate the safety profile of LHQW in relation to conventional drugs (PROSPERO CRD-42020224180). [12], In April 2022, the Financial Times reported that the leading COVID-19 health official in the PRC, the famous epidemiologist and pulmonologist Zhong Nanshan - who has also been the most prominent scientific promoter of Lianhua Qingwen - had undisclosed prior investments in large stakeholdings in corporations producing Lianhua Qingwen and other treatments under question. Adv. Dang Y., Xu J., Yang Y., Li C., Zhang Q., Zhou W., Zhang L., Ji G. Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine. There was no statistically significant difference in the incidence of adverse reactions during treatment of COVID-19 pneumonia between the LHQW group and the conventional drug group (RR = 0.51, 95% CI = 0.141.82, p = 0.297). [Caprifoliaceae; Lonicerae Japonicae Flos] (255g), Ephedra sinica Stapf [Ephedraceae; Ephedrae Botanical drug] (85g), Prunus armeniaca L. [Rosaceae; Armeniacae Semen Amarum] (85g), Gypsum Fibrosum (255g), Isatis indigotica Fort. Lianhua Qingwen, the traditional Chinese medicine recently approved for use in the Philippines by the country's Food and Drugs Administration (FDA), only treats symptoms of the coronavirus disease 2019 (COVID-19), and not the disease itself, a traditional Chinese medicine physician said Tuesday. Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review. Yu P., Li Y.Z., Wan S.B., Wang Y. Efficacy of Lianhua Qingwen granules combined with abidor in the treatment of mild COVID-19. This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. 52 (3), 5860. 13:764774. doi: 10.3389/fphar.2022.764774. A total of 420 participants with influenza (ages from 18 years to 65 years) were randomly divided into three groups: high dose LHQW capsule treatment (6 capsules each time, bid), low dose LHQW capsule treatment (4 capsules of LHQW+2 capsules of placebo each time, bid) and placebo intervention (6 capsules of placebo each time, bid). Yang C.X., Qu J., Liu Y.T., Meng S.W., Wang B.L., Feng M.Q., Sun Y. Received 2020 Jul 3; Revised 2020 Aug 9; Accepted 2020 Aug 16. Control. Two studies reported psychiatric disorders as the adverse reaction. During the study, no serious adverse events were reported. No statistical difference was detected for sleepy. Wang S.H., Liu J.F., Zhang Y.L., Dong Z. The clinical application experience of LHQW has improved over the years, the clinical considers the patients condition, physical quality, and age, controls the amount of LHQW prescribed accordingly and thereby, reduced the likelihood of adverse reactions. 132 studies documented gastrointestinal system damage. What Is in a Name? Pract. LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group (RR = 0.46, 95% CI = 0.290.74, p = 0.001). China Med. [4][7], Lianhua Qingwen should be avoided for patients with G6PD deficiency, since its active ingredient, Lonicera japonica, will lead to hemolysis to such patients. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Data from our meta-analysis also failed to compare the security of LHQW with conventional drugs for treatment of COVID-19 pneumonia, which requires further investigation. 228 (2), 8390. Chen J., Wang Y.K., Gao Y., Hu L.S., Yang J.W., Wang J.R., Sun W.J., Liang Z.Q., Cao Y.M., Cao Y.B. Lianhua Qingwen Prescription is approved for the treatment of fever, cough, and fatigue caused by light and common type of COVID-19 . Peng L.L., Li L., Shen L., Li X.L. Pharmacol. Anti Covid-19 Drugs: Need for More Clinical Evidence and Global Action. Niu Q.Q., Chen Y., Liu Y., Mao S.Z., Wang H., Zheng W.K., Zhang J.H. In the evaluation of security indexes, LHQW group has a reduced incidence of respiratory system damage, skin and its appendages injury, nervous system damage and gastrointestinal system damage, along with other adverse reactions. A Trial of Lopinavir-Ritonavir in Covid-19. The duration of sputum was shorter in the Lianhua Qingwen group than in the conventional drug group (WMD = 1.10, 95% CI = 1.50 to 0.70, < 0.001). (2021) investigated the efficacy and security of LHQW in the treatment of mild or moderate COVID-2019 pneumonia, reported no statistical difference in the incidence of adverse reactions between LHQW and conventional treatment groups from two studies (RR = 0.43, 95%CI = 0.121.54, p = 0.19). Available at: https://chemrxiv.org/engage/chemrxiv/article-details/60c74908ee301c485bc799cf (Accessed July 23, 2021). (2015). Now, there are no study results posted on ClinicalTrials.gov for this study yet. Chinese Herbal Medicine ("3 Medicines and 3 Formulations") for COVID 19: Rapid Systematic Review and MetaanalysisChinese Herbal Medicine ("3 Medicines and 3 Formulations") for COVID-19: Rapid Systematic Review and Meta-Analysis. On March 27, 2019, Yiling Pharmaceutical Co. Ltd. amended the LHQW drug manual to include adverse reactions related to its clinical application. Traditional Chinese medicine Lianhua Qingwen capsule has been proven effective for the treatment of COVID-19, China's top respiratory expert Zhong Nanshan said in a webinar with overseas Chinese students on Monday. [Cruciferae; Isatudus Radix], Dryopteris crassirhizoma Nakai [Polypodiaceae; Dryopteris Crassirhizomatis Rhizoma], Houttuynia cordata Thunb. CONTRAINDICATIONS Uncertainty. Experiments on animals using a combination of LHQW and oseltamivir to treat influenza B virus infections showed a potential inhibitory effect on overexpression of TNF-, MIP-1, RANTES, IFN-, IL-6, IL-8, IP-10, and MCP-1 at the mRNA level, and consequent prevented of the development of severe inflammatory reactions (Yang et al., 2020). Lianhua Qingwen combined with conventional treatment obviously improved COVID-19. The different incidence of these adverse reactions may be related to the metabolic level, which varies greatly among the different age groups. Guo H., Zhang Q.H., Yang J., Gong J.N., Zhao Y.S., Zhou X.P. Nevertheless, pressing researches should be conducted to illuminate the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19. In cases of I2 > 50%, obvious heterogeneity was defined and the random-effects model selected. Wang F.C., Shen B.X., He C.Y., Zhao W.C., Nie S.L. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. Lianhua Qingwen combined with conventional antiviral Western Medicine may be a useful treatment for prediabetes. Accordingly, other biases were defined as low risk of bias. The risk of bias data is presented as a percentage, as shown in Figure 2. (2021). Kunming: Kunming University of technology. Batlle D., Wysocki J., Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Compared with the conventional drug group, the incidence of disease recurrence was lower in the LHQW group, implied that LHQW might could regulate and enhance the immune function of the body. Hu K., Guan W.J., Bi Y., Zhang W., Li L., Zhang B., Liu Q., Song Y., Li X., Duan Z., Zheng Q., Yang Z., Liang J., Han M., Ruan L., Wu C., Zhang Y., Jia Z.H., Zhong N.S. Trim and Fill: a Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis. f. & Thoms.) J. Pharmacovigilance. Chin. There was no statistically significant difference in the incidence of adverse reactions during treatment of chronic obstructive pulmonary disease between the LHQW group and the conventional drug group (RR = 1.27, 95% CI = 0.513.17, p = 0.608). There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). The cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials. Furthermore, they identified two important metabolites, prostaglandin F2 and arachidonic acid, and their arachidonic acid metabolism pathway, as vital indicators of LHQW in treating influenza by using serum metabolomics analysis [19]. Efficacy and mechanism of Lianhua Qingwen Capsules(LHQW) on chemotaxis of macrophages in acute lung injury (ALI) animal model. 2020, 3196375. doi:10.1155/2020/3196375, Yao, K. T., Liu, M. Y., Li, X., Huang, J. H., and Cai, H. B. In addition, LHQW capsules could inhibit both Victoria and Yamagata lineages of influenza B virus (IBV) with the 50 % inhibitive concentrations ranging from 0.2280.150 to 0.7540.161mg/mL [26]. Advances in Pharmacology and Clinical Research of Lianhua Qingwen Capsules. Objectives: Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. The following aspects were assessed for each study: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. We aim to assess the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in Clinical treatment of COVID-19 or asymptomatic infection. Hence, the researches on specific active components of LHQW are still important and the reduction of irrelevant ingredients may be related to less adverse reactions. Formulae. conducted another single center clinical trial which was showed that seven days after treatment with LHQW granules (6g, tid) in conjunction with conventional treatment for COVID-19 patients had a total effective rate of 92.73 % accompanied by significantly reduced major symptoms including fever, cough, fatigue and chest tightness [41]. government site. A recent meta-analysis came from Zhang and Liu, (2014), focused on treatment for influenza A (H1N1) with LHQW in conjunction with oseltamivir. Z., Wang, H. T., Han, X., Liu, C., Sun, Y. N., Liu, B., et al. doi:10.14009/j.issn.1672-2124.2013.08.001, Wang, Y. A study by Lei (2020) on childhood influenza treatment revealed no statistical difference of adverse effects between LHQW group and conventional drug group (p = 0.751), inconsistent with our meta-analysis. LHQW was initially approved by the China Food and Drug Administration (CFDA) in 2004 and represents the first traditional Chinese medicine that passed the rapid drug approval channel of CFDA for treatment of severe acute respiratory syndrome (SARS). LHQW capsules not only had hemagglutination inhibition activity against B/Guangzhou/0215/2012 of influenza B virus, but also inhibited the over-expression of RANTES, IL-6, IL-8, IP-10, TNF-, MCP-1, macrophage inflammatory protein (MIP)-1, and interferon (IFN)- at the mRNA level and prevented a severe inflammatory response [26]. Efficacy and Safety of Lianhuaqingwen for Mild or Moderate Coronavirus Disease 2019. Second, one purposes of this study was to retrieve information on adverse reactions from different countries, due to language barriers, only English and Chinese articles were retrieved, and adverse reactions in the Chinese population were specifically analyzed, the effects on populations from other countries therefore require further investigation. Hsieh C.F., Lo C.W., Liu C.H., Lin S., Yen H.R., Lin T.Y., Horng J.T. Further long-term high-quality studies are essential to validate our conclusions. In total, 95 studies reported randomization data while 93 did not provide information on randomization, and the remaining 29 were grouped according to order of intervention or hospitalization. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Contraindications . Recent advances have discovered that COVID-19 is a systematic disease targeting the lungs, vasculatures, and immune system, and involves severe lung inflammation and immune deficiency in terms of cytokine storm, neutrophil extracellular traps, as well as imbalance of lymphocyte subsets and so forth [[4], [5], [6]]. Drugs and Clinic. All authors approved the final version of this manuscript. doi:10.1126/science.367.6485.1412, Lei, X. Further investigation confirmed that the combination treatment of LHQW capsules (200mg/kg/day) with oseltamivir (2mg/kg/day) markedly reduced IBV infection over the individual administration of either alone in vivo, proving that LHQW capsules could be used as an assistant drug to enhance the effect of oseltamivir against IBV infection [26]. (Lianqiao), Lonicera japonica Thunb. Pulmonary Rale.Eighteen studies reported an effect on the duration of pulmonary rale. Subgroup analysis was performed based on adverse reactions and sensitivity analysis implemented to investigate the influence of each study on the overall evaluation by excluding studies in turn. The Trim and Fill method was further applied to assess the impact of publication bias. Subgroup analysis revealed that LHQW group has a reduced incidence of rash than the conventional drug group (RR = 0.58, 95% CI = 0.390.86, p = 0.007), no statistical difference was detected for itchy skin. Pharmacopoeia of Peoples Republic of China. Broad Anti-viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-gan Granule and Rational Use against Covid-19 Based on Literature Mining. Considerable research to date has focused on the clinical efficacy of LHQW, the safety of LHQW is additionally an important consideration for clinical application that should not be neglected. For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). LYY19H280006, No. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. The Plant List (2021). J. Nanjing Univ. Available at: http://www.theplantlist.org/(Accessed December 18, 2021). 8600 Rockville Pike 339 (7), b2535. 2017ZYY07). Moreover, LHQW capsule also remarkably decreased the infectivity of H3N2 in vitro [25]. Prof. Zhenhua Jia formulates the prescription of Lianhua Qingwen based on the theory of collateral disease, and participates in the research projects of Lianhua Qingwen against H 1 N 1 and COVID-19. In a lipopolysaccharide (LPS)-induced acute lung injury animal model, LHQW could efficiently decrease the chemotaxis of monocytes toward the pulmonary infection foci, and thus blocked the disease development by down-regulating MCP-1 expression [33]. Lianhua Qingwen Capsules/granules Product Details. 25 (4), 727790728729. 160, 105101. doi:10.1016/j.phrs.2020.105101, Xiao, M., Tian, J., Zhou, Y., Xu, X., Min, X., Lv, Y., et al. Chin. Li L.C., Kan L.D. Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia. There was no statistically significant difference in the incidence of psychiatric disorders between the LHQW group and the conventional drug group (RR = 1.00, 95% CI = 0.253.97, p = 1.000). [19], Although the medicine has been allowed to be sold in Canada since 2012, Health Canada has cautioned against the use of the Chinese traditional medicine to prevent, treat, and cure COVID-19. The documents were filtered and summarized for final evaluation. Four studies reported body as a whole-general disorders as an adverse event. Vahl. Objectives: Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. As Chinese Pharmacopoeia records, LHQW consists of 13 ingredients: Forsythia suspensa (Thunb.) [Cruciferae; Isatudus Radix] (255g), Dryopteris crassirhizoma Nakai [Polypodiaceae; Dryopteris Crassirhizomatis Rhizoma] (255g), Houttuynia cordata Thunb. The post-marketing monitoring data incorporated information on the following gastrointestinal adverse reactions: nausea, diarrhea, vomiting, abdominal pain, abdominal distension, dry mouth; as well as skin rash, itching, dizziness (Yiling Pharmaceutical, 2021). 66 (6), 771777. There was no statistically significant difference in the incidence of adverse reactions during treatment of viral influenza between the LHQW group and the conventional drug group (RR = 0.75, 95% CI = 0.471.21, p = 0.244). The results remained statistically robust after different number supplement of potential studies (for hepatobiliary system damage: RR = 0.90, 95% CI = 0.60 to 1.34; for psychiatric disorders: RR = 1.00, 95% CI = 0.20 to 4.91; for gastrointestinal system damage: RR = 0.86, 95% CI = 0.76 to 0.98; for body as a whole-general disorders: RR = 0.73, 95% CI = 0.212.56). Herald. Several limitations of our meta-analysis should be taken into consideration. Inclusion in an NLM database does not imply endorsement of, or agreement with, Efficacy of Lianhua Qingwen Compared With Conventional Drugs in the Treatment of Common Pneumonia and Covid-19 Pneumonia: a Meta-Analysis. Li H.R., Chang L.P., Wei C., Jia Z.H. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). Theoretical research basis and clinical efficacy of Lianhua Qingwen in treating Novel Coronavious pneumonica. Materia Med. man dies from elephant poop, feeling hungover when pregnant second trimester, california car modification laws 2022,

Fujian Cuisine Recipes, Alignment Of Senior High School Strand In College Course, Articles L